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SUMMARY. To evaluate the accuracy of liver transient elas-
tography (TE), spleen TE and other noninvasive tests
(AAR, APRI score, platelet count, platelet/spleen ratio) in
predicting the presence and the size of oesophageal varices
in compensated hepatitis C virus (HCV) cirrhosis, we stud-
ied 112 consecutive patients with compensated HCV cir-
rhosis who underwent biochemical tests, gastrointestinal
endoscopy, liver TE and spleen TE by Fibroscan (Echo-
sens, Paris, France) using a modified software version with
a range between 1.5 and 150 kPa. Spleen TE was not
reliable in 16 patients (14.3%). Among the 96 patients
with a valid measurement (69.8% men, mean age:
63.2  9.5 years), 43.7% had no oesophageal varices,
29.2% had grade 1% and 27.1% had grade 2 or grade 3
oesophageal varices. Patients with values of 75 kPa by
standard spleen TE had mean values of modified spleen TE
of 117 kPa (range: 81.7149.5). Linear regression
revealed3 a significant correlation between modified spleen
TE and oesophageal varix size (r = 0.501; beta: 0.763, SE:
0.144; P < 0.001). On univariate analysis, the variables
associated with grade 2/grade 3 oesophageal varices were
AAR score, APRI score, platelet/spleen ratio, liver TE and
modified spleen TE. On multivariate analysis, only modified
spleen TE (OR: 1.026; 95% CI: 1.0071.046; P = 0.006)
and AAR (OR: 14.725; 95% CI: 1.928112.459;
P = 0.010) remained independently associated with grade
2/grade 3 oesophageal varices. Platelet/spleen ratio was
the best predictor of oesophageal varices area under the
ROC curve (AUROC: 0.763, cut-off: 800, sensitivity: 74%,
specificity: 70%), while modified spleen TE was more accu-
rate in predicting grade 2/grade 3 oesophageal varices
(AUROC: 0.82, cut-off: 54.0 kPa, sensitivity: 80%, specific-
ity: 70%). Portal hypertension increases spleen stiffness,
and the measurement of modified spleen TE is an accurate,
noninvasive tool for predicting the presence of large
oesophageal varices in patients with compensated HCV
cirrhosis.
Keywords: cirrhosis, liver stiffness, oesophageal varices,
spleen stiffness, transient elastography.
INTRODUCTION
The diagnosis of5 cirrhosis and portal hypertension is the
principal decision-making point to consider in patients with
chronic liver disease due to hepatitis C virus (HCV) infection
[1]. Although liver biopsy is the mainstay for the assess-
ment of fibrosis and the diagnosis of cirrhosis [2], and eval-
uation of oesophageal varices (EV) is made by endoscopy
[3,4], noninvasive methods could conceivably replace these
procedures [58]. Several studies [911] and two meta-
analyses [12,13] have shown that liver stiffness measure-
ment by transient elastography (TE) is the most accurate
noninvasive method for detecting cirrhosis in patients with
chronic HCV hepatitis. However, when liver TE was used to
indirectly evaluate the degree of portal hypertension and
the likelihood of presence of EV [11,1416], the results
were less satisfactory. Similarly, the platelet count [17], the
measurement of the spleen diameter by ultrasound scan
(US) [18] and, in particular, the platelet count/spleen diam-
eter ratio [19,20], while having been identified as noninva-
sive methods to classify patients with cirrhosis and EV, still
lack in sensitivity and specificity.
In patients with cirrhosis, splenomegaly is caused both
by portal congestion, and tissue hyperplasia and fibrosis.
Abbreviations: EV, oesophageal varices 4; HCV, hepatitis C Virus; LS,
liver stiffness; ROC, receiver operating characteristic curves; SS,
spleen stiffness; TE, transient elastography; US, ultrasound scan.
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Histological observation of the spleen in patients with cir-
rhosis shows a pooling of blood in the red pulp of the
spleen, hyperplasia of histiocytes and myofibroblasts, and
an increase in reticular fibres and hyperplasia of arterials
[21]. The increase in spleen size is followed by an increase
in splenic blood flow, which actively participates in portal
hypertension by congesting the portal system [22]. The
rapid decrease in outflow resistance of the splenic vein, fol-
lowed by a slow decrease in spleen size and by an increase
in the platelet count after liver transplantation, confirms
that both splenic haemodynamics and splenomegaly are
caused by congestion and tissue hyperplasia [23,24].
The hypothesis of our study was that spleen stiffness
measurement by TE could conceivably be a noninvasive
measure of portal hypertension and the likelihood of the
presence of oesophageal varices. With this aim, we planned
a prospective observational study that included patients
with compensated liver cirrhosis secondary to HCV to eval-
uate spleen TE as a diagnostic tool.
PATIENTS AND METHODS
Patients
In this prospective study, we included patients with a new
clinical or histological diagnosis of HCV Child-Pugh A cir-
rhosis and who underwent gastrointestinal endoscopy
(GIE) as screening for EV. All patients had a serum HCV
RNA positivity by PCR (Roche TaqMan HCV ver 2.0, Basel,
Switzerland6 ). We excluded patients with HIV and/or HBV
co-infection, history of alcohol abuse (20 g/day in the
last year or more, evaluated by questionnaire) or previous
liver decompensation and/or variceal bleeding, diagnosis of
hepatocellular carcinoma (HCC) and/or portal thrombosis,
and patients on treatment with b-blockers. The study was
carried out in accordance with the principles of the Decla-
ration of Helsinki and approved by our hospital’s Ethics
Committee. All patients gave written informed consent to
perform TE of the liver and the spleen as an extra clinical
procedure.
Procedures
All patients included in the study underwent single-day
haematological and biochemical tests, abdominal ultra-
sound scan (US) examination, liver and spleen TE, and
GIE. Haematological (platelet count, leucocyte count and
haemoglobin levels) and liver function (bilirubin, albumin,
AST/ ALT levels and prothrombin time) tests were con-
ducted to evaluate the Child-Pugh score, the AST/ALT
ratio (AAR), the AST-to-platelet ratio index (APRI) and the
platelet count/spleen diameter ratio. US and TE were per-
formed by FibroScan™ (Echosens, Paris, France) after over-
night fasting. By US, we evaluated liver structure to
exclude patients with HCC and the presence of ascites. We
also measured the longitudinal diameter of the spleen.
Liver stiffness (LS) was evaluated in the right lobe of the
liver through intercostal spaces, with the patient in the
supine position and the right arm in maximal abduction
[25]. The longitudinal diameter of the spleen was mea-
sured by US with the patient in the supine position and
the left arm in maximal abduction. Under US guidance,
the axis of the FibroScan™ probe was placed perpendicular
to the plane of the thorax in the intercostal space corre-
sponding to the spleen parenchyma. In all patients, at least
10 measurements of LS and spleen stiffness (SS) were
taken. The success rate was calculated as the ratio of the
number of successful measurements to the total number of
acquisitions. Median values of the successful measurements
were kept as representative of LS and SS, and results were
expressed in kilopascal (kPa). Only examinations with at
least 10 valid measurements and a success rate of more
than 60% were considered reliable. TE of the liver and the
spleen was performed by two expert physicians (V.C., F.B.).
To assess interobserver variability, 15 patients selected at
random were evaluated by both operators, each of whom
was blinded to the results obtained by the other. The con-
cordance coefficient between interobserver evaluations was
0.97. STE was analysed first with standard FibroScan™
software and subsequently with a modified software ver-
sion, not commercially available, and provided by Echo-
sens, which allows measurement of stiffness between 1.5
and 150 kPa, defined as modified spleen stiffness (mSS).
GIE was performed in all patients by a single operator
(F.S.), and oesophageal varices were graded according to
the North Italian Endoscopic Club for the Study and Treat-
ment of Esophageal Varices [26]. EV were classified as
small (G1), when they occupied less than 30% of the
lumen; medium (G2), when occupying between 30% and
60% of the lumen; and large (G3), if more than 60% of
the lumen was occupied.
Statistics
Continuous variables were summarized as mean  SD and
categorical variables as frequency and percentage. Multiple
logistic regression models were used to assess the relation-
ship between demographic, biochemical and instrumental
data and to detect the presence of EV. We selected age,
gender, AST/ALT ratio (AAR), AST-to-platelet ratio index
(APRI), platelet count, spleen diameter, platelet count/
spleen diameter ratio, LS, SS and mSS as noninvasive vari-
ables associated with the presence of EV and/or large EV.
Variables found to be associated with the dependent vari-
ables on univariate logistic regression with a probability
threshold of <0.05 were included in the multivariate logis-
tic regression models. Regression analysis was performed
using the SPSS statistical package (version 15.0; SPSS Inc,
Chicago, IL, USA). Using MedCalc statistical 7software, we
obtained the receiver operating characteristic (ROC) curves
© 2013 John Wiley & Sons Ltd
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and the best cut-off for identifying the area under the ROC
curve (AUROC) of LTE and STE for predicting the presence
of EV and large EV in patients with compensated cirrhosis.
Sensitivity (Se), specificity (Sp), positive and negative pre-
dictive values (PPV and NPV), positive likelihood ratio
(+LR) and negative likelihood ratio (LR) were calculated
using cut-offs resulting in a diagnosis of compensated cir-
rhosis with EV.
RESULTS
Patient features
One hundred and twelve patients with clinical or histologi-
cal diagnosis of compensated cirrhosis were included in the
study between January 2008 and March 2011. In 16
cases (14.3%), TE of the spleen was not conclusive, and
these patients were excluded from the study. In six of
them, all with a body mass index (BMI) 30, also TE of
the liver could not be performed (5.3% of the whole
cohort). Ninety-six patients were analysed. Sixty-seven of
them (69.8%) were men, the mean age was
63.2  9.5 years, and the mean BMI was 27.0  3.0 kg/
sm. The mean values of albumin, bilirubin and INR were
4.0  0.3 g/dL, 1.1  0.6 mg/dL and 1.0  0.18 , respec-
tively. Seventy-six patients had a Child-Pugh score (CPS) of
5, and 20 patients a CPS of 6. EV were found in 54
patients (56.3%), with 28 patients (29.2%) having grade 1
EV, 17 patients (17.7%) having grade 2 and 9 patients
(9.4%) having grade 3.
Standard spleen stiffness in the evaluation of oesophageal
varices
The mean spleen diameter was significantly lower in the 16
patients without a reliable SS measurement compared with
the 96 patients with a reliable spleen stiffness evaluation
(12.3  2.4 cm vs 14.6  2.9 cm; P = 0.005). The mean
SS value for the entire cohort was 48.7  20.6 kPa. In 21
cases (21.7%), the SS value was equal to 75 kPa. As shown
in Table 1, we observed a significant difference in mean SS
values between patients without EV and those with EV
(44.7  17.9 kPa vs 55.6  19.5 kPa; P = 0.006). Simi-
larly, as shown in Table 3, the mean values of SS were sig-
nificantly lower in patients without EV or with grade 1 EV
than the values observed in patients with grade 2 or grade 3
EV (45.3  18.7 kPa vs 64.7  13.6 kPa; P < 0.001).
Modified spleen stiffness in the evaluation of oesophageal
varices
All SS measurements were then analysed by Echosens,
using a software version that allows measurement of stiff-
ness between 1.5 and 150 kPa. Figure 1 shows the distri-
Table 1 Clinical and biochemical features of 96 patients with compensated HCV cirrhosis according to the presence of EV
Cirrhosis without EV
(42 patents)
Cirrhosis with EV
(54 patients) P value
Multivariate analysis
OR (95% CI) P value
Gender (Male,%) 28 (66.7) 39 (72.0) 0.566  
Age (years, mean, SD) 60.7  10.5 65.1  8.2 0.122  
AST (U/L, mean, SD) 89.0  63.4 89.5  74.8 0.970  
ALT (U/L, mean, SD) 120.3  91.3 93.1  60.4 0.101  
AST/ALT ratio 0.78  0.25 1.02  0.33 <0.001 7.363 (1.18245.844) 0.032
PLT (9103/mL) 128.5  41.8 89.6  35.5 <0.001  
APRI test 1.86  1.36 2.73  2.00 0.017 0.989 (0.6801.439) 0.954
Spleen diameter (cm) 14.1  3.1 15.0  2.8 0.157  
PLT count /spleen
diameter ratio
981.3  390.6 628.1  278.9 <0.001 0.998 (0.9960.999) 0.006
Liver Stiffness (kPa, mean, SD) 17.9  9.4 25.7  14.0 0.002 1.012 (0.9561.072) 0.678
SR (%, mean, SD) 85.7  17.6 85.3  24.6 0.935
IQR (mean, SD) 3.4  2.0 4.6  4.5 0.101
Spleen Stiffness (kPa, mean, SD) 44.4  18.4 55.3  19.6 0.007  
SR (%, mean, SD) 82.8  15.1 82.7  15.2 0.968  
IQR (mean, SD) 9.7  7.8 8.9  8.9 0.624  
Modified Spleen Stiffness
(kPa, mean, SD)
48.4  26.3 69.4  39.5 0.002 1.011 (0.9941.029) 0.214
SR (%, mean, SD) 82.8  15.1 82.7  15.2 0.968
IQR (mean, SD) 17.1  14.5 18.7  12.2 0.559
AST, aspartate aminotransferase; ALT, alanine aminotransferase; EV, oesophageal varices; HCV, hepatitis C virus; IU, Inter-
national units; INR, international normalized ratio; PLT, platelets. SD, standard deviation.
© 2013 John Wiley & Sons Ltd
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bution of standard SS and mSS mean values calculated for
patients with compensated HCV cirrhosis with different EV
grades. All 21 patients (21.9%) who had values of 75 kPa
by standard TE had a mean mSS value of 118 KPa, with a
range from 81.7 to 149.5 kPa. The rate of patients with
EV (50.7% vs 76%, P = 0.028) and with grade 2 or grade
3 EV (19.7% vs 56% P = 0.001) was significantly different
between patients with an mSS lower or higher than
75 KPa. Furthermore, on linear regression analysis, we
found a higher regression coefficient between EV size and
mSS (r = 0.501; beta: 0.763, SE: 0.144, P < 0.001) than
between EV size and SS (r = 0.437; beta 0.382, SE 0.081
P < 0.001). Taking into account the higher correlation
coefficient of mSS with EV, we decided to use this instead
of the SS for analysis of the data.
Noninvasive serum fibrosis tests, liver stiffness and
modified spleen stiffness in predicting the presence of
oesophageal varices
Patients with EV had a significantly higher value of AST/
ALT ratio, platelet count, APRI, spleen diameter, PLT
count/spleen diameter ratio, LS and mSS on univariate
analysis (Table 1). On multivariate analysis, only AAR
(OR: 7.363; 95% CI, 1.18245.884; P = 0.032) and PLT
count/spleen diameter ratio (OR: 0.998; 95% CI, 0.996
0.999; P = 0.006) were independently associated with the
presence of EV (Table 1). ROC curve analysis identified the
PLT/Spleen ratio as the noninvasive test of fibrosis that
achieved the best performance for predicting EV (AUROC:
0.763, cut-off: 800, sensitivity: 74%, specificity: 70%, PPV:
77%, NPV: 67%). The best cut-off value of modified SS for
predicting EV was 50.0 kPa (AUROC 0.70, sensitivity:
65%, specificity: 61%, PPV: 69%, NPV: 57%; Table 2).
Noninvasive serum fibrosis tests, liver stiffness and
modified spleen stiffness in predicting the presence of
large oesophageal varices
Similarly, we performed a univariate analysis to identify
the clinical and biochemical variables associated with the
presence of grade 2 or grade 3 varices in patients with
compensated HCV cirrhosis. As expected, the difference in
mean AST/ALT ratio, platelet count, APRI, spleen diame-
ter, PLT count/spleen diameter ratio, LS and mSS were
found to be statistically significant between patients with-
out EV or with small EV and patients with large varices
(Table 3). On multivariate analysis, the independent pre-
dictors of grade 2 or grade 3 varices were AAR (OR:
14.725, 95% CI: 1.928112.459; P = 0.010) and mSS
(OR: 1.026, 95% CI: 1.0071.046; P = 0.006) only
(Table 3). On AUROC analysis, mSS was the more accurate
tool for predicting grade 2 or grade 3 EV (AUROC: 0.82,
cut-off: 54.0 kPa, sensitivity: 80%, specificity: 70%, PPV:
47%, NPV: 90%; Table 4).
DISCUSSION
Various studies [911] and two meta-analyses [12,13]
assessing the diagnostic accuracy of liver TE in staging
fibrosis in patients with chronic hepatitis C have reported
Fig. 1 Distribution of spleen stiffness and median modified
spleen stiffness values calculated for patients with
compensated hepatitis C virus cirrhosis at different grades
of oesophageal varices.
Table 2 Performances of liver stiffness and spleen stiffness in predicting EV in 96 patients with compensated HCV-related
liver cirrhosis
Prevalence
54/96
(56.3%) AUROC Cut-off SE 95% CI
Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%) +LR  LR
Correctly
classified (%)
LS (kPa) 0.707 17.0 0.054 0.600.80 71 57 67 62 1.7 0.5 60 (62.5)
Modified SS 0.701 50.0 0.056 0.570.77 65 61 69 57 1.7 0.6 60 (62.5)
AAR 0.732 0.80 0.051 0.630.82 69 67 73 62 2.1 0.5 66 (69)
APRI 0.657 1.5 0.056 0.550.75 67 52 64 55 1.6 0.6 58 (60.4)
PLT/Spleen 0.763 800.0 0.051 0.660.84 74 70 77 67 2.5 0.4 68 (71)
AUROC, area under the ROC curve, EV, oesophageal varices; HCV, hepatitis C virus; LR, likelihood ratio; LS, liver stiffness;
NPV, negative predictive values; PPV, positive predictive values.
© 2013 John Wiley & Sons Ltd
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an NPV higher than 90% for the diagnosis of cirrhosis,
suggesting greater accuracy in excluding than in confirm-
ing it, although liver TE is inaccurate in the assessment of
portal hypertension [11,1416,27]. Although Kazemi et al.
[16] demonstrated that an LS 19 kPa had a 93% NPV
for the presence of large varices, suggesting a potential role
for TE in selecting patients for endoscopic screening, a
study by Vizzuti et al. [14], while finding a solid correlation
between LS and the hepatic venous pressure gradient
(HVPG), rated TE quite poorly in predicting and grading
EV, based on a negative predictive value of 66%. In a
study by Bureau et al. [15], LS correlated with the pres-
ence of EV, although no association between LS values and
the size of EV was found. Castera et al. [11] reported the
optimized cut-offs for the detection of EV at 21.5 kPa (73%
of patients correctly classified) and large EV at 30.5 kPa
(79% of patients correctly classified). However, they found
that several blood markers (platelets, AST/ALT ratio, Fibro-
Test, prothrombin index, Lok index) performed better than
TE for predicting both EV and large EV. Finally, in a recent
study [28], our group reported that in patients with
compensated HCV cirrhosis, the platelet/spleen ratio and
Table 3 Clinical and biochemical features of 96 patients with compensated HCV cirrhosis according to the presence of
large EV
No EV, Small EV
(70 patents)
Large EV
(26 patients) P value
Multivariate analysis
OR (95% CI) P value
Gender (Male, %) 47 (67.1) 20 (76.9) 0.354  
Age (years, mean, SD) 62.5  9.4 64.9  9.7 0.275  
AST (U/L, mean, SD) 87.4  58.4 94.3  94.7 0.670  
ALT (U/L, mean, SD) 111.9  80.6 86.6  60.8 0.150  
AST/ALT ratio 0.84  0.27 1.13  0.34 <0.001 14.725 (1.928112.459) 0.010
PLT (9103/mL) 114.7  41.9 85.0  38.1 0.002  
APRI 2.13  1.50 2.95  2.35 0.045 1.38 (0.7311.474) 0.834
Spleen diameter (cm) 14.1  2.9 15.8  2.9 0.011 0.770 (0.4801.236) 0.280
PLT count /spleen diameter ratio 865.2  377.1 555.8  257.4 <0.001 0.992 (0.9811.004) 0.211
Liver stiffness (kPa, mean, SD) 20.0  10.7 28.2  15.7 0.005 0.990 (0.9441.037) 0.663
SR (%, mean, SD) 86.7  21.5 82.2  22.4 0.372
IQR (mean, SD) 3.5  2.5 5.5  5.4 0.100
Spleen stiffness (kPa, mean, SD) 45.3  19.0 64.6  14.1 <0.001  
SR (%, mean, SD) 82.7  15.8 83.0  13.2 0.930  
IQR (mean, SD) 9.6  7.5 8.3  10.5 0.556  
Modified spleen stiffness
(kPa, mean, SD)
50.7  30.0 85.8  38.1 <0.001 1.026 (1.0071.046) 0.006
SR (%, mean, SD) 82.7  15.8 83.0  13.2 0.930
IQR (mean, SD) 16.7  13.6 21.4  11.6 0.120
AST, aspartate aminotransferase; ALT, alanine aminotransferase; EV, oesophageal varices; HCV, hepatitis C virus; IU, Inter-
national units; INR, international normalized ratio; PLT, platelets; SD, standard deviation.
Table 4 Performances of liver stiffness and spleen stiffness in predicting large EV in 96 patients with compensated HCV-
related liver cirrhosis
Prevalence
26/96
(27.1%) AUROC Cut-off (kPa) SE 95% CI
Sens.
(%)
Spec.
(%) PPV (%) NPV (%) +LR  LR
Correctly
classified (%)
LS (kPa) 0.710 19.0 0.060 0.610.80 72 55 38 84 1.6 0.5 54 (56.2)
Modified SS 0.819 54.0 0.053 0.700.86 80 70 47 90 2.0 0.3 66 (68.9)
AAR 0.751 1.0 0.058 0.650.83 69 72 49 86 2.5 0.4 65 (67.7)
APRI 0.631 2.0 0.064 0.530.73 60 56 33 78 1.3 0.7 55 (57.3)
PLT/Spleen 0.740 640 0.054 0.640.83 73 65 44 86 2.1 0.4 64 (66.7)
AUROC, area under the ROC curve; EV, oesophageal varices; HCV, hepatitis C virus; LR, likelihood ratio; LS, liver stiffness;
NPV, negative predictive values; PPV, positive predictive values.
© 2013 John Wiley & Sons Ltd
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insulin resistance measured by HOMA-IR, regardless of the
presence of diabetes, significantly predicted the presence of
EV, outweighing the contribution offered by TE.
We hypothesized that the measurement of spleen stiff-
ness by TE could be a noninvasive method for evaluating
the presence of EV. To determine whether SS could con-
ceivably be a noninvasive measure capable of evaluating
the likelihood of presence of EV, we carried out this pro-
spective observational study, including consecutive
patients with compensated HCV cirrhosis evaluated for the
presence of oesophageal varices. This possibility was
already suggested by Stefanescu et al. [29] in a study
describing the correlation between SS values and the pres-
ence of EV and more recently by Colecchia et al. [30]
who evaluated 113 patients with a diagnosis of liver cir-
rhosis. Similar to this study, we enrolled 112 patients
with newly diagnosed compensated HCV cirrhosis who
had measurement of liver and spleen stiffness on the same
day as GIE. The rate of SS measurement failure is similar
in the two studies (14% vs 11%).This was due to a high
BMI in some, but more frequently due to a success rate of
measurement of less than 60%. SS measurement failed
less frequently in patients with larger measurable volume
of the spleen. In fact, it was easier to localize, under US
guidance, the middle of the region of interest (ROI) in a
spleen with a longitudinal diameter of at least 12 cm and
a mean anteroposterior diameter of 4 cm. In addition, the
prevalence of EV was analogous (54% vs 53%) in the two
studies, and similar cut-off values for diagnosis of EV were
reported. However, Colecchia et al. [30] found an overall
higher performance of TE of the spleen for diagnosis of EV
compared with our study. The higher age of our cirrhotic
patients with a more stabilized portal hypertension dem-
onstrated by a larger spleen diameter and lower platelets
count could be associated with the development of many
portosystemic collateral shunts. This may represent a pos-
sible explanation of the different performance of SS in
diagnosing the presence of EV. Further studies evaluating
the role of the spleen stiffness in diagnosing portal hyper-
tension may clarify better this issue. Furthermore, Colec-
chia et al. [30] did not analyse the performance of
noninvasive tests for diagnosis of large varices. Indeed,
Baveno guidelines recommend a primary prophylaxis with
beta-blockers or variceal band ligation in these patients,
and defining the role of spleen stiffness for diagnosis of
large EV could be relevant in the management of patients
with liver cirrhosis. Actually, in our cohort of patients,
mSS has been the more accurate tool for predicting grade
2 or grade 3 EV with an AUROC of 0.82 and a NPV of
90%.
Furthermore, given our high rate of patients with an SS
value 75 kPa, we asked Echosens to revise our spleen
stiffness results to confirm the data and to evaluate the
exact range of values of the spleen stiffness. To overcome a
potential ceiling effect, Echosens performed an analysis of
the data using software that allows measurement of a stiff-
ness between 1.5 and 150 kPa.
Our study, in addition to the assessment of LS and SS,
included, in parallel, an analysis of the performance of
such noninvasive tests as the AST/ALT ratio, APRI test
and platelet count/spleen diameter ratio in predicting cir-
rhosis with EV. Previous studies have concluded that LS
cannot replace endoscopy as screening for EV in patients
with cirrhosis [11,14,15]. In our study, LS was confirmed
as having a modest sensitivity and specificity in discrimi-
nating cirrhotic patients with EV, because, as in other
studies, the test correctly identified less than 65% of
patients.
In addition, mSS performed more poorly than PLT/spleen
count and AAR in diagnosing EV, although when we anal-
ysed the performances of the noninvasive tool in diagnos-
ing the presence of grade 2 or grade 3 EV, mSS performed
better. The best cut-off of mSS for predicting the presence
of large EV was set by ROC curve at 54 kPa and
obtained an AUROC of 0.82 and an NPV of 90%, suggest-
ing that in patients with cirrhosis, the performance of mSS
in predicting the presence of grade 2 or 3 EV was clearly
better than that of LS and also better than any other bio-
chemical or instrumental variable linked to portal hyper-
tension, such as longitudinal spleen diameter, platelets and
even the platelet count/spleen diameter ratio, which is con-
sidered the most sensitive predictor of EV in this setting
[19,20].
We have found an high odds ratio of AAR in predicting
both EV and large EV. This datum is not completely new.
Indeed, Castera et al. [11] have shown that the ability of
AAR in diagnosing EV was higher than TE of the liver in
their cohort of patients with cirrhosis. However, Colecchia
et al. [30] did not report the performance of AAR in their
study. Further studies are needed to address this issue.
This study has same limitations. First, we used a Fibro-
Scan™ probe validated only for the measurement of LS.
Indeed, the acquisition parameters of the Fibroscan were
optimized for stiffness assessment of liver tissues, especially
in terms of low-frequency excitation. To accurately assess
the stiffness of organs harder than the liver, the acquisition
parameters (low-frequency excitation, pulse repetition fre-
quency) should be modified. Normal spleen stiffness is
reported to be higher than that of the liver. Therefore,
despite the use of a modified algorithm, the use of the
Fibroscan on the spleen of patients with cirrhosis might
lead to overestimated stiffness values. The vascular struc-
ture and the small volume of the spleen could be a limita-
tion for the measurement of spleen stiffness. Furthermore,
presence of ascites represents another important limitation
for these patients. Indeed, it is not unusual that we need to
diagnose the oesophageal varices in patients with decom-
pensated cirrhosis. However, in collaboration with Echo-
sens, which allowed an extension of the upper limit of
measurement, we were able to obviate the problem of a
© 2013 John Wiley & Sons Ltd
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high rate of spleen stiffness values 75 kPa, which is the
upper value of the measure scale of the FibroScan™. This
allowed us to identify the correct range of spleen stiffness
values and discover that FibroScan™ can be a useful tool
for measuring it. Another clinically important issue that
needs to be assessed in the future is the evaluation of the
impact of beta-blockers on the mSS. The use of mSS in this
setting could avoid the repetition of the portosystemic gra-
dient measurement, reducing the costs and the discomfort
of patients.
In conclusion, our data suggest that mSS can help clini-
cians in identifying compensated cirrhosis with clinically
significant portal hypertension. After external validation in
large, independent settings in a larger number of patients
with cirrhosis of various aetiologies, these data might lead
to avoidance of universal endoscopic screening.
AUTHORS’ CONTRIBUTIONS 9
V. Di Marco, V.Calvaruso and A. Craxı were involved in
the study concept and design; V. Calvaruso, F. Bronte, E.
Conte and F. Simone contributed to the acquisition of data;
V. Calvaruso and V. Di Marco were involved in analysis
and data interpretation; V.Calvaruso and V. Di Marco
drafted the manuscript; V. Di Marco and A, Craxı involved
in the critical revision of the manuscript; V. Calvaruso per-
formed statistical analysis.
CONFLICT OF INTERESTS
None.
REFERENCES
1 Ghany MG, Strader DB, Thomas DL
et al. Diagnosis, management, and
treatment of hepatitis C: an update.
Hepatology 2009; 49: 13351374.
2 Bedossa P, Carrat F. Liver biopsy:
the best, not the gold standard. J
Hepatol 2009; 50: 13.
3 de Franchis R. Evolving consensus
in portal hypertension. Report of the
Baveno IV consensus workshop on
methodology of diagnosis and ther-
apy in portal hypertension. J Hepatol
2005; 43: 167176.
4 Garcia-Tsao G, Bosch J, Groszmann
RJ. Portal hypertension and variceal
bleedingunresolved issues. Sum-
mary of an American Association
for the study of liver diseases and
European Association for the study
of the liver single-topic conference.
Hepatology 2008; 47: 17641772.
5 Rockey DC, Bissell DM. Noninvasive
measures of liver fibrosis. Hepatology
2006; 43: S113S120.
6 Castera L. Transient elastography
and other noninvasive tests to assess
hepatic fibrosis in patients with viral
hepatitis. J Viral Hepat 2009; 16:
300314.
7 Bosch J. Towards the non-invasive
diagnosis of cirrhosis: the nuts-cir-
rhosis connection. J Hepatol 2009;
50: 46.
8 de Franchis R. Non-invasive (and
minimally invasive) diagnosis of
oesophageal varices. J Hepatol 2008;
49: 520527.
9 Foucher J, Chanteloup E, Vergniol J
et al. Diagnosis of cirrhosis by tran-
sient elastography (FibroScan): a
prospective study. Gut 2006; 55:
403408.
10 Ganne-Carrie N, Ziol M, de Leding-
hen V et al. Accuracy of liver stiff-
ness measurement for the diagnosis
of cirrhosis in patients with chronic
liver diseases. Hepatology 2006; 44:
15111517.
11 Castera L, Le Bail B, Roudot-Thora-
val F et al. Early detection in rou-
tine clinical practice of cirrhosis and
oesophageal varices in chronic
hepatitis C: comparison of transient
elastography (FibroScan) with
standard laboratory tests and non-
invasive scores. J Hepatol 2009; 50:
5968.
12 Friedrich-Rust M, Ong MF, Martens
S et al. Performance of transient
elastography for the staging of liver
fibrosis: a meta-analysis. Gastroen-
terology 2008; 134: 960974.
13 Talwalkar JA, Kurtz DM, Schoenle-
ber SJ et al. Ultrasound-based tran-
sient elastography for the detection
of hepatic fibrosis: systematic review
and meta-analysis. Clin Gastroenterol
Hepatol 2007; 5: 12141220.
14 Vizzutti F, Arena U, Romanelli RG
et al. Liver stiffness measurement
predicts severe portal hypertension
in patients with HCV-related cirrho-
sis. Hepatology 2007; 45: 1290
1297.
15 Bureau C, Metivier S, Peron JM et al.
Transient elastography accurately
predicts presence of significant portal
hypertension in patients with
chronic liver disease. Aliment Phar-
macol Ther 2008; 27: 12611268.
16 Kazemi F, Kettaneh A, N’Kontchou
G et al. Liver stiffness measurement
selects patients with cirrhosis at risk
of bearing large oesophageal vari-
ces. J Hepatol 2006; 45: 230235.
17 Lackner C, Struber G, Liegl B et al.
Comparison and validation of sim-
ple noninvasive tests for prediction
of fibrosis in chronic hepatitis C.
Hepatology 2005; 41: 13761382.
18 Schepis F, Camma‘ C, Niceforo D
et al. Which patients should
undergo endoscopic screening for
oesophageal varices detection? Hepa-
tology 2001; 33: 333338.
19 Giannini E, Botta F, Borro P et al.
Platelet count/spleen diameter ratio:
proposal and validation of a non-
invasive parameter to predict the
presence of oesophageal varices in
patients with liver cirrhosis. Gut
2003; 52: 12001205.
20 Giannini E, Zaman A, Kreil A et al.
Platelet count/spleen diameter ratio
for the non invasive diagnosis of
oesophageal varices. Results of a
multicenter, prospective, validation
study. Am J Gastroenterol 2006;
101: 25112519.
21 Manenti F, Williams R. Injection
studies of the splenic vasculature in
portal hypertension. Gut 1966; 7:
175180.
22 Bolognesi M, Merkel C, Sacerdoti D
et al. Role of spleen enlargement in
cirrhosis with portal hypertension.
Dig Liver Dis 2002; 34: 144150.
© 2013 John Wiley & Sons Ltd
Spleen transient elastography and oesophageal varices in cirrhosis 7
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
23 Piscaglia F, Zironi G, Gaiani S et al.
Systemic and splanchnic hemody-
namic changes after liver transplan-
tation for cirrhosis: a long-term
prospective study. Hepatology 1999;
30: 5864.
24 Bolognesi M, Sacerdoti D, Bombona-
to G et al. A. Change in portal flow
after liver transplantation: effect on
hepatic arterial resistance indices
and role of spleen size. Hepatology
2002; 35: 601608.
25 Sandrin L, Fourquet B, Hasquenoph
JM et al. Transient elastography: a
new noninvasive method for assess-
ment of hepatic fibrosis. Ultrasound
Med Biol 2003; 29: 17051713.
26 The North Italian Endoscopic Club
for the Study and Treatment of
Esophageal Varices. Prediction of the
first variceal hemorrhage in patients
with cirrhosis of the liver and esoph-
ageal varices. A prospective multi-
center study. N Engl J Med 1988;
319: 983989.
27 Thabut D, Moreau R, Lebrec D. Non-
invasive assessment of portal hyper-
tension in patients with cirrhosis.
Hepatology 2011; 53(2): 683694.
28 Camma C, Petta S, Di Marco V et al.
Insulin resistance is a risk factor for
esophageal varices in hepatitis C
virus cirrhosis. Hepatology 2009;
49: 195203.
29 Stefanescu H, Grigorescu M, Lupsor
M, Procopet B, Maniu A, Badea R.
Spleen stiffness measurement using
Fibroscan for the noninvasive
assessment of esophageal varices in
liver cirrhosis patients. J Gastroenter-
ol Hepatol 2011; 26(1): 164170.
30 Colecchia A, Montrone L, Scaioli E
et al. Measurement of spleen stiff-
ness to evaluate portal hypertension
and the presence of esophageal var-
ices in patients with HCV-related
cirrhosis. Gastroenterology. 2012;
?????: ?????????.10
© 2013 John Wiley & Sons Ltd
8 V. Calvaruso et al.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
Author Query Form
Journal: JVH
Article: 12114
Dear Author,
During the copy-editing of your paper, the following queries arose. Please respond to these by marking up
your proofs with the necessary changes/additions. Please write your answers on the query sheet if there is
insufficient space on the page proofs. Please write clearly and follow the conventions shown on the attached
corrections sheet. If returning the proof by fax do not write too close to the paper’s edge. Please remember
that illegible mark-ups may delay publication.
Many thanks for your assistance.
Query reference Query Remarks
1 AUTHOR: Please check edit made in the article title.
2 AUTHOR: Please provide qualification and role for corresponding author.
3 AUTHOR: Please check and confirm whether the change of “varices” to its singular
form as “varix” in the sentence “Linear regression revealed a … oesophageal varix
size (r = 0.501; beta: 0.763, SE: 0.144; p<0.001)” is ok.
4 AUTHOR: The term “esophageal” has been changed as “oesophageal” as per the
language requirement of the style sheet. Please suggest whether the abbreviation of
“ES” also needs to be changed.
5 AUTHOR: Please check and confirm whether the edit made in the sentence “The
diagnosis of cirrhosis … virus (HCV) infection” is appropriate.
6 AUTHOR: Please provide manufacturer name here.
7 AUTHOR: Please check and confirm whether the capitalization change made in the
software name “MedCalc” in the sentence “Using MedCalc statistical software …
with compensated cirrhosis” is appropriate.
8 AUTHOR: Please provide appropriate unit here.
9 AUTHOR: Please check and confirm whether the edits made in the Authors’ contri-
bution section are appropriate.
10 AUTHOR: Please provide the volume number, page range for reference [30].
O n c e y o u h a v e A c r o b a t R e a d e r o p e n o n y o u r c o m p u t e r , c l i c k o n t h e C o m m e n t t a b a t t h e r i g h t o f t h e t o o l b a r :
S t r i k e s a l i n e t h r o u g h t e x t a n d o p e n s u p a t e x t
b o x w h e r e r e p l a c e m e n t t e x t c a n b e e n t e r e d .
‚ H i g h l i g h t a w o r d o r s e n t e n c e .
‚ C l i c k o n t h e R e p l a c e ( I n s ) i c o n i n t h e A n n o t a t i o n s
s e c t i o n .
‚ T y p e t h e r e p l a c e m e n t t e x t i n t o t h e b l u e b o x t h a t
a p p e a r s .
T
h i s w i l l o p e n u p a p a n e l d o w n t h e r i g h t s i d e o f t h e d o c u m e n t .
T
h e m a j o r i t
y
o f
t o o l s
y
o u w i l l u s e f o r a n n o t a t i n g
y
o u r p r o o f w i l l b e i n t h e A n n o t a t i o n s s e c t i o n ,
p i c t u r e d o p p o s i t e . W e ’ v e p i c k e d o u t s o m e o f t h e s e t o o l s b e l o w :
S t r i k e s a r e d l i n e t h r o u g h t e x t t h a t i s t o b e
d e l e t e d .
‚ H i g h l i g h t a w o r d o r s e n t e n c e .
‚ C l i c k o n t h e S t r i k e t h r o u g h ( D e l ) i c o n i n t h e
A n n o t a t i o n s s e c t i o n .
H
i g h l i g h t s t e x t i n
y
e l l o w a n d o p e n s u p a t e x t
b
o x w h e r e c o m m e n t s c a n
b
e e n t e r e d .
‚ H i g h l i g h t t h e r e l e v a n t s e c t i o n o f t e x t .
‚ C l i c k o n t h e A d d n o t e t o t e x t i c o n i n t h e
A n n o t a t i o n s s e c t i o n .
‚ T y p e i n s t r u c t i o n o n w h a t s h o u l d b e c h a n g e d
r e g a r d i n g t h e t e x t i n t o t h e
y
e l l o w
b
o x t h a t
a p p e a r s .
M
a r k s a p o i n t i n t h e p r o o f w h e r e a c o m m e n t
n e e d s t o
b
e h i g h l i g h t e d .
‚ C l i c k o n t h e A d d s t i c k y n o t e i c o n i n t h e
A n n o t a t i o n s s e c t i o n .
‚ C l i c k a t t h e p o i n t i n t h e p r o o f w h e r e t h e c o m m e n t
s h o u l d
b
e i n s e r t e d .
‚ T y p e t h e c o m m e n t i n t o t h e y e l l o w b o x t h a t
a p p e a r s .
I n s e r t s a n i c o n l i n k i n g t o t h e a t t a c h e d f i l e i n t h e
a p p r o p r i a t e p a c e i n t h e t e x t .
‚ C l i c k o n t h e A t t a c h F i l e i c o n i n t h e A n n o t a t i o n s
s e c t i o n .
‚ C l i c k o n t h e p r o o f t o w h e r e y o u ’ d l i k e t h e a t t a c h e d
f i l e t o b e l i n k e d .
‚ S e l e c t t h e f i l e t o b e a t t a c h e d f r o m y o u r c o m p u t e r
o r n e t w o r k .
‚ S e l e c t t h e c o l o u r a n d t y p e o f i c o n t h a t w i l l a p p e a r
i n t h e p r o o f .
C
l i c k O K .
I n s e r t s a s e l e c t e d s t a m p o n t o a n a p p r o p r i a t e
p l a c e i n t h e p r o o f .
‚ C l i c k o n t h e A d d s t a m p i c o n i n t h e A n n o t a t i o n s
s e c t i o n .
‚ S e l e c t t h e s t a m p y o u w a n t t o u s e . ( T h e A p p r o v e d
s t a m p i s u s u a l l y a v a i l a b l e d i r e c t l y i n t h e m e n u t h a t
a p p e a r s ) .
‚ C l i c k o n t h e p r o o f w h e r e y o u ’ d l i k e t h e s t a m p t o
a p p e a r . ( W h e r e a p r o o f i s t o b e a p p r o v e d a s i t i s ,
t h i s w o u l d n o r m a l l y b e o n t h e f i r s t p a g e ) .
A l l o w s s h a p e s , l i n e s a n d f r e e f o r m a n n o t a t i o n s t o b e d r a w n o n p r o o f s a n d f o r
c o m m e n t t o b e m a d e o n t h e s e m a r k s . .
‚ C l i c k o n o n e o f t h e s h a p e s i n t h e D r a w i n g
M a r k u p s s e c t i o n .
‚ C l i c k o n t h e p r o o f a t t h e r e l e v a n t p o i n t a n d
d r a w t h e s e l e c t e d s h a p e w i t h t h e c u r s o r .
‚ T o a d d a c o m m e n t t o t h e d r a w n s h a p e ,
m o v e t h e c u r s o r o v e r t h e s h a p e u n t i l a n
a r r o w h e a d a p p e a r s .
‚ D o u b l e c l i c k o n t h e s h a p e a n d t y p e a n y
t e x t i n t h e r e d b o x t h a t a p p e a r s .
